person · Reporting owner

Requadt Scott

Disclosed activity across 6 companies

Tapewire entity: 74247
SEC CIK: 0001664852

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ESSA Pharma Inc.EPIX · Entity 15763	Director	October 09, 2025	October 15, 2025
Entasis Therapeutics Holdings Inc.ETTX · Entity 16036	10% owner	September 28, 2018	October 02, 2018
Forty Seven, Inc.FTSV · Entity 16035	10% owner	July 02, 2018	July 02, 2018
Tectonic Therapeutic, Inc.AVRO · Entity 5328	Director	June 25, 2018	June 25, 2018
Tourmaline Bio, Inc.TALS · Entity 15643	Former Chief Executive Officer	July 03, 2023	July 06, 2023
VBI Vaccines Inc/BCVBIV · Entity 111039	Director	January 31, 2019	February 04, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ESSA Pharma Inc.

Report date October 09, 2025 · Filed October 15, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2025-10-09 transaction · row 1 1 source row Row 1 · 2025-10-09 · Disposition to issuer · Disposed 30,002 · Balance 0 F1: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.

Entasis Therapeutics Holdings Inc.

Report date September 28, 2018 · Filed October 02, 2018

Jointly reported with Clarus Lifesciences III, L.P., Clarus Ventures III GP, L.P., Clarus Ventures III, LLC, Simon Nicholas, LIPTAK ROBERT, HENNER DENNIS, WHEELER KURT

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	361,829	Reported balance After 2018-09-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-09-28 · Conversion · Acquired 361,829 · Balance 361,829 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	685,170	Reported balance After 2018-09-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-09-28 · Conversion · Acquired 323,341 · Balance 685,170 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,170,010	Reported balance After 2018-09-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-09-28 · Conversion · Acquired 412,583 · Balance 1,170,010 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3: This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,623,405	Reported balance After 2018-09-28 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2018-09-28 · Purchase · Acquired 453,395 · Balance 1,623,405 F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2018-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-09-28 · Conversion · Disposed 7,500,000 · Balance 0 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Series B-1 Tranche A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2018-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-09-28 · Conversion · Disposed 6,702,213 · Balance 0 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Series B-1 Tranche B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2018-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-09-28 · Conversion · Disposed 8,552,024 · Balance 0 F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

F3: This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.

Forty Seven, Inc.

Report date July 02, 2018 · Filed July 02, 2018

Jointly reported with Clarus Lifesciences III, L.P., Clarus Ventures III GP, L.P., Clarus Ventures III, LLC, HENNER DENNIS, GALAKATOS NICHOLAS, LIPTAK ROBERT, Simon Nicholas, WHEELER KURT

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee foonote	938,489	Reported balance After 2018-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-02 · Conversion · Acquired 938,489 · Balance 938,489 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,816,951	Last balance in matching sequence After 2018-07-02 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2018-07-02 · Conversion · Acquired 755,780 · Balance 1,694,269 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Row 3 · 2018-07-02 · Conversion · Acquired 1,922,682 · Balance 3,616,951 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Row 4 · 2018-07-02 · Purchase · Acquired 200,000 · Balance 3,816,951 F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-02 · Conversion · Disposed 938,489 · Balance 0 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.
Series A-2 Preferred StockSEC Table II · derivative / convertible security	IndirectSee foonote	0	Reported balance After 2018-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-02 · Conversion · Disposed 755,780 · Balance 0 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-02 · Conversion · Disposed 1,922,682 · Balance 0 F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest.

Tectonic Therapeutic, Inc.

Report date June 25, 2018 · Filed June 25, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	2,962,325	Last balance in matching sequence After 2018-06-25 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-06-25 · Conversion · Acquired 2,283,434 · Balance 2,283,434 F1: Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Row 2 · 2018-06-25 · Conversion · Acquired 678,891 · Balance 2,962,325 F3: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-06-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-06-25 · Conversion · Disposed 9,435,150 · Balance 0 F3: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2018-06-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-06-25 · Conversion · Disposed 2,805,179 · Balance 0 F3: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.

F2: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any.

F3: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.

F4: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.

Tourmaline Bio, Inc.

Report date July 03, 2023 · Filed July 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	578,403	Reported balance After 2023-07-03 transaction · row 1 1 source row Row 1 · 2023-07-03 · Tax withholding · Disposed 11,786 · Balance 578,403 F1: The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.
Common StockSEC Table I · non-derivative	IndirectSee footnote	449,766	Reported balance Holding disclosure · report date 2023-07-03 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 449,766 F2: These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023.

F2: These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.

VBI Vaccines Inc/BC

Report date January 31, 2019 · Filed February 04, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.67 · Expires 2029-01-31	Direct	200,000	Reported balance After 2019-01-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-01-31 · Grant · Acquired 200,000 · Balance 200,000 F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date.

F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 09, 2025 Filed Oct 15, 2025 11:58 UTC	ESSA Pharma Inc. EPIX · Entity 15763	Disposition to issuerCommon Shares	30,002	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-099650 · tm2528208-3_4seq1.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement. Read SEC document
March 25, 2024 Filed Mar 28, 2024 12:38 UTC	ESSA Pharma Inc. EPIX · Entity 15763	GrantOptions · Derivative	50,000	$0.00 Strike: $9.04	$0.00	Disclosure SEC source: 0000950172-24-000138 · form4.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2034-03-25 Read SEC document
November 06, 2023 Filed Jan 16, 2024 13:41 UTC	ESSA Pharma Inc. EPIX · Entity 15763	OtherCommon Shares	12,500	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001597 · doc4.xml · nonDerivative · entry 2 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,002 F1 · kind: Reflects a transfer pursuant to a property settlement agreement. Read SEC document
October 30, 2023 Filed Jan 16, 2024 13:41 UTC	ESSA Pharma Inc. EPIX · Entity 15763	OtherCommon Shares	17,502	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001597 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,502 F1 · kind: Reflects a transfer pursuant to a property settlement agreement. Read SEC document
July 03, 2023 Filed Jul 6, 2023 17:19 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	Tax withholdingCommon Stock	11,786	$3.08	$36,300.88	Disclosure SEC source: 0001209191-23-041610 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,403 F1 · price: The restricted stock units ("RSUs") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023. Read SEC document
February 01, 2023 Filed Feb 3, 2023 17:01 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Appreciation Right · Derivative	320,000	$0.00 Strike: $1.73	$0.00	Disclosure SEC source: 0001209191-23-006998 · doc4.xml · derivative · entry 4 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2033-02-01 F4 · derivative.exercise_date: Each Time Vested Stock Appreciation Right ("TV SAR") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date. F4 · derivative.underlying_shares: Each Time Vested Stock Appreciation Right ("TV SAR") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TVSAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date. Read SEC document
February 01, 2023 Filed Feb 3, 2023 17:01 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Option (Right to Buy) · Derivative	320,000	$0.00 Strike: $1.73	$0.00	Disclosure SEC source: 0001209191-23-006998 · doc4.xml · derivative · entry 3 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2033-02-01 F3 · derivative.exercise_date: The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024. Read SEC document
December 30, 2022 Filed Feb 3, 2023 17:01 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantCommon Stock	4	$0.87	$3.47	Disclosure SEC source: 0001209191-23-006998 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,193 F1 · kind: These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c). Read SEC document
September 10, 2022 Filed Sep 13, 2022 16:30 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantCommon Stock	80,000	$0.00	$0.00	Disclosure SEC source: 0000899243-22-030931 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,189 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. F2 · balance_after: Includes 1,509 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document
July 29, 2022 Filed Aug 2, 2022 17:02 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	PurchaseCommon Stock	39,382	$4.25	$167,373.50	Disclosure SEC source: 0000899243-22-027404 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,680 Read SEC document
July 28, 2022 Filed Jul 28, 2022 19:52 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	PurchaseCommon Stock	3,090	$4.25	$13,132.50	Disclosure SEC source: 0000899243-22-026986 · doc4.xml · nonDerivative · entry 2 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,298 Read SEC document
July 26, 2022 Filed Jul 28, 2022 19:52 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	PurchaseCommon Stock	5,528	$4.24	$23,438.72	Disclosure SEC source: 0000899243-22-026986 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,208 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
July 22, 2022 Filed Jul 26, 2022 19:38 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	PurchaseCommon Stock	9,444	$3.75	$35,412.17	Disclosure SEC source: 0000899243-22-026759 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,680 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.735 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
June 29, 2022 Filed Nov 1, 2022 11:07 UTC	ESSA Pharma Inc. EPIX · Entity 15763	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $3.60	$0.00	Disclosure SEC source: 0001209191-22-054971 · doc4.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2032-06-29 F1 · derivative.exercise_date: 100% of the options vest after 12 months from the date of grant. Read SEC document
February 01, 2022 Filed Feb 2, 2022 18:01 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantStock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $9.10	$0.00	Disclosure SEC source: 0000899243-22-004202 · doc4.xml · derivative · entry 3 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-01-31 F3 · derivative.exercise_date: The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter. Read SEC document
December 31, 2021 Filed Feb 2, 2022 18:01 UTC	Tourmaline Bio, Inc. TALS · Entity 15643	GrantCommon Stock	1,470	$13.00	$19,110.00	Disclosure SEC source: 0000899243-22-004202 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,236 F1 · kind: These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c). Read SEC document
December 11, 2020 Filed Jan 11, 2021 16:45 UTC	ESSA Pharma Inc. EPIX · Entity 15763	GrantStock Option (Right to Buy) · Derivative	16,500	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001209191-21-002952 · doc4.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2030-12-11 F1 · derivative.exercise_date: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter. Read SEC document
December 11, 2020 Filed Jan 26, 2021 19:02 UTC Amendment	ESSA Pharma Inc. EPIX · Entity 15763	GrantStock Option (Right to Buy) · Derivative	16,500	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001209191-21-005512 · doc4a.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2030-12-11 F1 · derivative.exercise_date: Vesting terms have been amended such that 100% of the options vest after 12 months from the date of grant. Read SEC document
January 31, 2019 Filed Feb 4, 2019 17:13 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	GrantOption (Right to Buy Common Shares) · Derivative	200,000	$0.00 Strike: $1.67	$0.00	Disclosure SEC source: 0001493152-19-001335 · ownership.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B-1 Tranche B Convertible Preferred Stock · Derivative	8,552,024	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · derivative · entry 7 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 412,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B-1 Tranche A Convertible Preferred Stock · Derivative	6,702,213	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · derivative · entry 6 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 323,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionSeries B Convertible Preferred Stock · Derivative	7,500,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · derivative · entry 5 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 361,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.underlying_shares: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	PurchaseCommon Stock	453,395	$15.00	$6,800,925.00	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · nonDerivative · entry 4 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,623,405 F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	412,583	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · nonDerivative · entry 3 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,170,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · balance_after: This number includes an aggregate of 72,257 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	323,341	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · nonDerivative · entry 2 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 685,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:36 UTC	Entasis Therapeutics Holdings Inc. ETTX · Entity 16036	ConversionCommon Stock	361,829	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-053534 · doc4.xml · nonDerivative · entry 1 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner HENNER DENNIS · CIK 0001249153 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 361,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reportable securities are held directly by Clarus Lifesciences III, L.P. ("Clarus III"). Clarus Ventures III GP, L.P. ("Clarus III GP") is the sole general partner of Clarus III. Clarus Ventures III, LLC ("Clarus III GP LLC") is the sole general partner of Clarus III GP. Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler are the managing directors of Clarus III GP LLC (the "Managing Members"). Each of Clarus III GP, Clarus III GP LLC and the Managing Members may be deemed to beneficially own the securities held by Clarus III. Each of Clarus III GP, Clarus III GP LLC and the Managing Members disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionSeries B Preferred Stock · Derivative	1,922,682	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · derivative · entry 7 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,922,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionSeries A-2 Preferred Stock · Derivative	755,780	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · derivative · entry 6 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonote Disclosed balance after: 0 Underlying: Common Stock · 755,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionSeries A-1 Preferred Stock · Derivative	938,489	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · derivative · entry 5 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 938,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	PurchaseCommon Stock	200,000	$16.00	$3,200,000.00	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · nonDerivative · entry 4 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,816,951 F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionCommon Stock	1,922,682	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · nonDerivative · entry 3 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,616,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionCommon Stock	755,780	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · nonDerivative · entry 2 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,694,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
July 02, 2018 Filed Jul 2, 2018 17:14 UTC	Forty Seven, Inc. FTSV · Entity 16035	ConversionCommon Stock	938,489	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-040426 · doc4.xml · nonDerivative · entry 1 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner HENNER DENNIS · CIK 0001249153 · Director · 10% owner GALAKATOS NICHOLAS · CIK 0001252522 · 10% owner LIPTAK ROBERT · CIK 0001252523 · 10% owner Simon Nicholas · CIK 0001431403 · 10% owner Requadt Scott · CIK 0001664852 · 10% owner WHEELER KURT · CIK 0001252525 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See foonote Disclosed balance after: 938,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's preferred stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Clarus Ventures III GP, LP, or GPLP, as the sole general partner of Clarus Lifesciences III, LP, or Clarus, may be deemed to beneficially own certain of the shares held by Clarus. GPLP disclaims beneficial ownership of all shares held by Clarus in which the GPLP does not have a pecuniary interest. Clarus Ventures III, LLC, or GPLLC, as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. GPLLC disclaims beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest. Each of Dennis Henner, Nicholas Galakatos, Robert Liptak, Nicholas Simon, Scott Requadt and Kurt Wheeler, as individual managing directors of GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Henner and Messrs. Galakatos, Liptak, Simon, Requadt and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which they do not have an actual pecuniary interest. Read SEC document
June 25, 2018 Filed Jun 25, 2018 18:18 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	ConversionSeries B Preferred Stock · Derivative	2,805,179	$0.00	$0.00	Disclosure SEC source: 0000899243-18-017968 · doc4.xml · derivative · entry 4 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 678,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document
June 25, 2018 Filed Jun 25, 2018 18:18 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	ConversionSeries A Preferred Stock · Derivative	9,435,150	$0.00	$0.00	Disclosure SEC source: 0000899243-18-017968 · doc4.xml · derivative · entry 3 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,283,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document
June 25, 2018 Filed Jun 25, 2018 18:18 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	ConversionCommon Stock	678,891	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-017968 · doc4.xml · nonDerivative · entry 2 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,962,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document
June 25, 2018 Filed Jun 25, 2018 18:18 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	ConversionCommon Stock	2,283,434	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-017968 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,283,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document
June 14, 2018 Filed Jun 18, 2018 10:51 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	Exercise / conversionRestricted Stock Units (RSUs) · Derivative	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-18-008820 · form4.xml · derivative · entry 2 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. F2 · derivative.expiration_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document
June 14, 2018 Filed Jun 18, 2018 10:51 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	Exercise / conversionCommon Shares, no par value per share	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-18-008820 · form4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document
January 23, 2018 Filed Jan 25, 2018 14:51 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	GrantOption (Right to Buy Common Shares) · Derivative	75,000	$0.00 Strike: $4.19	$0.00	Disclosure SEC source: 0001493152-18-001034 · form4.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 23, 2018 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 23, 2018 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document
June 14, 2017 Filed Jun 16, 2017 17:59 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	Exercise / conversionRestricted Stock Units (RSUs) · Derivative	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-17-006780 · form4.xml · derivative · entry 2 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 12,500 shares Expires 2026-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document
June 14, 2017 Filed Jun 16, 2017 17:59 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	Exercise / conversionCommon Shares, no par value per share	12,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-17-006780 · form4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document
March 31, 2017 Filed Apr 4, 2017 18:24 UTC	VBI Vaccines Inc/BC VBIV · Entity 111039	GrantOption (Right to Buy Common Shares) · Derivative	12,500	$0.00 Strike: $3.79	$0.00	Disclosure SEC source: 0001493152-17-003498 · form4.xml · derivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires 2027-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approvedthe option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated March 31, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.